TECENTRIQ HYBREZA
Live / Registered — Registered (as of 29 Apr 2025)
What this means for you
Registered since 29 Apr 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97338550
- Registration number
- 7779001
- Mark type
- Stylized text
- Filed
- 30 Mar 2022
- Published for opposition
- 30 May 2023
- Registered
- 29 Apr 2025
- Attorney of record
- Jelena Libby
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases
Owner
- Genentech, Inc., South San Francisco, CA, US
- Genentech, Inc., South San Francisco, CA, US
- Genentech, Inc., South San Francisco, CA, US
Prosecution history
- 29 Apr 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 29 Apr 2025 — REGISTERED-PRINCIPAL REGISTER
- 09 Apr 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 Apr 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 07 Apr 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Jan 2025 — USE AMENDMENT FILED
- 31 Mar 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Jan 2025 — TEAS STATEMENT OF USE RECEIVED
- 09 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2024 — SOU EXTENSION 2 GRANTED
- 09 Jul 2024 — SOU EXTENSION 2 FILED
- 09 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 10 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jan 2024 — SOU EXTENSION 1 GRANTED
- 08 Jan 2024 — SOU EXTENSION 1 FILED